Results 321 to 330 of about 230,682 (392)

Clinical Significance of Skeletal Fat‐to‐Muscle Ratio in Idiopathic Hyperaldosteronism

Clinical Endocrinology, EarlyView.
ABSTRACT Objective The objective of this study is to evaluate the correlation between the fat‐to‐muscle ratio (FMR) and insulin resistance (IR) with aldosterone production among patients with idiopathic hyperaldosteronism (IHA). Methods Patients with primary aldosteronism were screened from those with secondary hypertension and then subtyped via ...
Yuhe Jiang, Dan Li, Cassie Chen Cao, Wenjing Feng, Ruidong Liu, Yinfei Xu, Caixia Cao   +6 more
wiley   +1 more source

Ramadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective Interventional Case‐Control Study

Clinical Endocrinology, EarlyView.
ABSTRACT Introduction Intermittent fasting (IF) exposes patients with adrenal insufficiency (AI) to complications related to undertreatment. We aimed to determine the effect of IF during Ramadan on the quality of life of patients with secondary adrenal insufficiency (SAI) compared to healthy controls.
Mariam Mabrouk, Melika Chihaoui, Jameleddine Sta, Chayma Belhadj Slimane, Ibtissem Oueslati, Meriem Yazidi, Fatma Chaker   +6 more
wiley   +1 more source

LC-MS/MS-Based Assay for Steroid Profiling in Peripheral and Adrenal Venous Samples for the Subtyping of Primary Aldosteronism. [PDF]

J Clin Hypertens (Greenwich)
Chen X, Li Q, Huang L, Wu P.
europepmc   +1 more source

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Ron T. Gansevoort   +4 more
wiley   +1 more source

Early reduction of skin potassium without sodium accumulation in the pathogenesis of salt sensitivity in primary aldosteronism. [PDF]

Front Pharmacol
Mlejnek P, Liška F, Šilhavý J, Večerková K, Šimáková M, Pravenec M, Kurtz TW.   +6 more
europepmc   +1 more source

Use of NT‐proBNP for the screening, diagnosis and risk‐stratification of left ventricular dysfunction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Heart failure (HF) is a major health problem, and preventing the onset of heart failure could have large cost implications for healthcare systems globally. Screening for heart failure and its precursor, left ventricular dysfunction, could allow patients to receive therapies shown to reduce the risk of incident heart failure, such as ACE ...
Pardeep S. Jhund
wiley   +1 more source

Subtyping of Primary Aldosteronism by Adrenal Venous Sampling.

Endocr Rev
Rossi GP, Battistel M, Seccia TM, Rossi FB, Rossitto G.   +4 more
europepmc   +1 more source

Bilateral adrenal adenomas with autonomous cortisol secretion from both glands and autonomous aldosterone secretion from the left adrenal: a case report. [PDF]

J Yeungnam Med Sci
Han JE, Yoo S, Lee SA, Koh G.
europepmc   +1 more source

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Cardiorenal effects of semaglutide in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk were investigated. Materials and Methods Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non‐fatal myocardial infarction, or non ...
Jingmin Zhou, Mansoor Husain, Yang Li, Wenyan Liu, Zewei Shen, Tina Vilsbøll, Junbo Ge   +6 more
wiley   +1 more source

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. [PDF]

Nephrol Dial Transplant
Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG.   +20 more
europepmc   +1 more source